Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248432 | 0.83 | HIF1A (0.55) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL11611268 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11611265 | 0.80 | CYP1A2 (0.50) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28193690 | 0.80 | CYP1A2 (0.55) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11021099 | 0.79 | MAPT (0.52) | HIF1ACYP2C19CHRM3CHRM2LMNA | |
| SCHEMBL20546662 | 0.78 | CYP1A2 (0.48) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27979604 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2HIF1ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3350095 | 0.78 | CHRM3 (0.50) | HIF1ACYP2C19CHRM3CHRM2LMNA | |
| SCHEMBL10685798 | 0.78 | CHRM3 (0.50) | CHRM3CHRM2LMNACYP2D6CHRM1 | |
| SCHEMBL8071145 | 0.78 | CHRM3 (0.50) | CHRM3CHRM2LMNACYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102264703-A | mesylate salt of 5- (2- { [6- (2, 2-difluoro-2-phenylethoxy) hexyl ] amino } -1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one as beta 2 adrenoreceptor agonist | — | 2011-11-30 | — | — | CN | claimed |
| US-20160158375-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-06-09 | — | — | US | disclosed |
| EP-2739616-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2014-06-11 | — | — | EP | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8658637-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| CN-103288729-A | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquin olin-2(1h)-one and its use in the treatment of pulmonary diseases | ALMIRALL SA | 2013-09-11 | — | — | CN | disclosed |
| CN-103228654-A | Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as JAK inhibitors | ALMIRALL SA | 2013-07-31 | — | — | CN | disclosed |
| US-20130137849-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2588127-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | Indiana University Research and Technology Corporation (US) | 2013-05-08 | — | — | EP | disclosed |
| CN-102933583-A | Heteroaryl imidazolone derivatives as JAK inhibitors | ALMIRALL SA | 2013-02-13 | — | — | CN | disclosed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| CN-1416424-A | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase | AVENTIS PHARMA DENTSCHLAND GMD (DE) | 2003-05-07 | — | — | CN | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-0966430-B1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO MCNEIL PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137849-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | DNPEP, PEPD, CNDP2 | SMN1; SMN2 2517/4885HIF1A 1467/4885CYP1A2 3082/4885 |
| US-20160158375-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | DNPEP, PEPD, CNDP2 | SMN1; SMN2 2517/4885HIF1A 1467/4885CYP1A2 3082/4885 |
| US-20030171585-A1 | Triphenylpropanamide compounds | PTGES, PTGES2, MPO | SMN1; SMN2 3101/4885HIF1A 1325/4885CYP1A2 1916/4885 |
| US-20020103217-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | SMN1; SMN2 4242/4885HIF1A 662/4885CYP1A2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.